Rationale for Correct Answer
The correct answer is: Peripheral edema
Peripheral edema was common in clinical trials of MET targeted agents, with any grade peripheral edema occurring in 54% of patients treated with capmatinib in the Geometry mono-1 trial and 54% of patients treated with tepotinib in the VISION trial.1,2 Crizotinib and savolitinib, which also have anti-MET activity, are commonly associated with this adverse effect.3 In the VISION trial, peripheral edema was associated with dose reductions (14% of patients), dose interruptions (16% of patients), and permanent discontinuation of tepotinib treatment (3.5% of patients).2 Hypertension, vision disorders, and skeletal fractures were not common adverse events encountered in these trials.1,2
References:
1. Wolf J et al. Presented at ASCO; June 2021. Abstract 9020.
2. Le X et al. Clin Cancer Res. 2022;28:1117-1126.
3. Nishio M et al. Target Oncol. 2022;17:597-604.